^
Association details:
| Biomarker: | ERG overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
Excerpt:
...low dose Olaparib altered the growth of both the ERG and ETV1 overexpressing primary human prostate cancer xenografts [MDA-PCa-133: p = 0.05 (day 8) and p < 0.01 (day 12, 16, 20, 24, 28 and 32); MDA-PCa-2b–T: p < 0.01 (day 8, 12 and 16)], but had no effect on the ETS-negative primary human xenograft model...
DOI:
https://dx.doi.org/10.1016%2Fj.ccr.2011.04.010
